Mitobridge is a company that provides Biology, Pharmacy and Therapeutics, Small molecule and more. Mitobridge is headquartered in United States Massachusetts. Mitobridge was founded in 2011. and was founded by Kazumi Shiosaki. Mitobridge has a total of 248 patents
Related Topics
BiologyPharmacy and TherapeuticsSmall moleculeLeber's hereditary optic neuropathyAcute kidney injuryDrug discoveryRare diseaseProof of conceptPathologyPharmaceuticsAptamerDrug designCancer researchToxicologyClinical researchBiophysicsDrug developmentBiopharmaceuticalBiochemistryExosome
visualizing technology portfolio of hot application areas and blank areas for Mitobridge
Time Range:
Overall
Overall
1 year
3 year
5 year
Application Domain L2
Application Domain L2
Application Domain L3
Application Domain L4
High-Tech Industry L1
High-Tech Industry L2
Tech Topic L2
Tech Topic L3
Timeline
Tech Topic L2
Tech Topic L2
Tech Topic L3
High-Tech Industry L1
High-Tech Industry L2
Application Domain L2
Application Domain L3
Application Domain L4
Download
Subsidiary Lists
Subsidiaries with patent applications for Mitobridge
Sign up to view the full data
Free Trial Now
Download
Top Related Companies
Sign up to view the full data
Free Trial Now
Mitobridge Frequently Asked Questions
What is Mitobridge's industry?
Mitobridge is in the industry of:Research and Development in the Physical, Engineering, and Life Sciences
What technical fields has Mitobridge researched?
Mitobridge has researched the technical fields related toBiologyPharmacy and TherapeuticsSmall moleculeLeber's hereditary optic neuropathyAcute kidney injuryDrug discoveryRare diseaseProof of conceptPathologyPharmaceuticsAptamerDrug designCancer researchToxicologyClinical researchBiophysicsDrug developmentBiopharmaceuticalBiochemistryExosome
Mitobridge is discovering and developing small molecule therapeutics that improve mitochondrial functions. Building upon the emerging scientific findings...
What is Mitobridge's official website?
Mitobridge's official website is http://www.mitobridge.com.